



PRESS RELEASE, August 30, 2019

## New member of the Board of Directors

**Rolf Lood, PhD, Associate professor, Research Team Leader at Lund University and Vice President R&D at Genovis AB, has been proposed as new Board member of SelectImmune Pharma to replace Björn Wullt, who has expressed a wish to step down in order to focus on his clinical work.**

Rolf Lood, who received his MSc in Biomedicine at Lund University and conducted postdoc studies at the Rockefeller University in New York, has been proposed as new Board member of SelectImmune Pharma AB. Rolf's research focuses on experimental infectious medicine, which includes a focus on the molecular mechanisms behind the spread of antibiotic resistance through bacteriophages. Rolf Lood has published some 30 scientific articles and is responsible for three patents.

Rolf Lood is proposed to replace Björn Wullt, who has found it difficult on a practical level to combine his work as Board member of SelectImmune Pharma with his clinical activities and has therefore expressed a wish to be given an opportunity to focus on the latter.

*"I would consider it a privilege to be involved in developing the outstanding research used by SelectImmune Pharma to create drugs that can cure large patient groups,"* says Rolf Lood.

*"Unfortunately, there just isn't enough time sometimes. As a major shareholder in SelectImmune Pharma, I am happy that such a well-qualified and competent person as Rolf Lood has expressed an interest in replacing me on SelectImmune's Board of Directors when I now focus on my clinical activities,"* says Björn Wullt.

*"We are delighted that SelectImmune can benefit from Rolf Lood's knowledge of infectious medicine, which will be valuable in our future development,"* says Catharina Svanborg, Chairman of the Board of SelectImmune Pharma.

The Board of Directors of SelectImmune Pharma AB will convene an extraordinary general meeting shortly when it will propose the election of Rolf Lood as a new Board member of the company.

**For more information, contact:**

Catharina Svanborg

Chairman of the Board, SelectImmune

Pharma AB, Telephone +46 709 42 65 49

E-mail: [Catharina.Svanborg@med.lu.se](mailto:Catharina.Svanborg@med.lu.se)

*SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The Company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.*